Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29523625.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0291.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Higher concentrations of TKIs, such as pazopanib, are associated with improved outcomes in advanced RCC. A phase III trial failed to show disease-free survival benefit to pazopanib in the adjuvant setting, but improved DFS was seen in patients with higher <i>C</i><sub>trough</sub> levels, supporting adequate drug exposure for optimal clinical outcome. <i>Clin Cancer Res; 24(13); 2979-80. ©2018 AACR</i><i>See related article by Sternberg et al., p. 3005</i>.
Medical subject headings
- Carcinoma, Renal Cell
- Kidney Neoplasms